Business information provider Thomson Reuters, US, has published a research report, 'The Changing Role of Chemistry in Drug Discovery' in recognition of the International Year of Chemistry, 2011. By tracking pharmaceutical industry data over the past decade along with insights from industry experts, the new report forecasts the end of the blockbuster drug era. In its place, the report suggests, a much more targeted, patient-specific approach will define the next decade for the pharmaceutical industry and the patients it serves.
The report leverages data and analytics from the Thomson Reuters Integrity drug discovery database. It analyses pharmaceutical industry productivity, patent data, changing dynamics in the new drug pipeline and trends in the use of biomarkers, among several other factors.
Thomson Reuters Integrity seeks to integrate biology, chemistry and pharmacology data on more than 320,000 compounds with demonstrated biological activity and almost 140,000 patent family records. It is projected to provide researchers with reliable, detailed information across multiple disciplines and from the perspective of a scientist. The aim is to support successful drug research and development.
Search for more Industry study reports
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
